Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6609 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-19 (tec.mx)
The knowledge economy: the engine that drives global transformation
Discover how Mexico is moving towards a knowledge economy, promoting innovation and technological development. Be part of this change
Read more
2025-02-12 (tradingview.com)
BIOGEN INC. SEC 10-K Report — News
Biogen Inc., a leading biopharmaceutical company specializing in neurological and rare disease treatments, has released its 2024 Form 10-K report. The report provides a comprehensive overview of the company's financial performance, business operations, strategic initiatives, and the challenges it f…
Read more
2024-02-13 (mmm-online.com)
Biogen’s revenue, profit shrink as company pivots to Leqembi prospects
A major drag on Biogen’s topline performance was the decline in multiple sclerosis product revenue.
Read more
2023-02-15 (informa.com)
Biogen CEO Plots A Slow Return To Growth As Revenue Set To Shrink Again In 2023
Christopher Viehbacher told his first earnings call as CEO that a review is under way to reverse Biogen’s fortunes, but noted Leqembi will not be a meaningful contributor while treatment and reimbursement bottlenecks remain.
Read more
2021-07-22 (fiercebiotech.com)
Biogen takes $542M hit over 2 failed gene therapy trials as Aduhelm revenue trickles in
In case you missed it, Biogen had two high-profile gene therapy failures in the middle of the Aduhelm craze—and now they’re going to pay for it, literally. | Biogen had two high profile gene therapy failures in the middle of the Aduhelm craze, and now they’re going to pay for it.
Read more
2021-03-04 (fiercepharma.com)
Biogen cements gene therapy ambitions with $200M factory in Research Triangle
As Biogen awaits an FDA decision on its controversial Alzheimer's disease hopeful aducanumab, the company is setting the stage for an entry into the hot gene therapy field. | As Biogen works to diversify its revenue streams, it 's laying the groundwork for a gene therapy manufacturing plant at its
Read more